A predictive biomimetic model of cytokine release induced by TGN1412 and other therapeutic monoclonal antibodies

Journal of Immunotoxicology

Volumn 9, Issue 1, 2012, Pages 34-42

  Dhir, Vipra ^a   Fort, Madeline ^b   Mahmood, Ayesha ^a   Higbee, Russell ^a   Warren, William ^a   Narayanan, Padma ^b   Wittman, Vaughan ^a  

^a SANOFI PASTEUR   (France)

^b AMGEN INC   (United States)

Author keywords

Cytokine release assay; Immunotherapy; In vitro model; Monoclonal antibody; TGN1412

Indexed keywords

ALEMTUZUMAB; BEVACIZUMAB; COLLAGEN; CYTOKINE; GAMMA INTERFERON; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MONOCLONAL ANTIBODY; OKT 3; TGN 1412; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BIOMIMETICS; CONTROLLED STUDY; CYTOKINE RELEASE; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; LEUKOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHYSIOLOGY; PREDICTION; PRIORITY JOURNAL; THROMBOCYTE POOR PLASMA;

ANTIBODIES, MONOCLONAL, HUMANIZED; BIOMIMETICS; CELLS, CULTURED; COCULTURE TECHNIQUES; COLLAGEN; CYTOKINES; DRUG EVALUATION, PRECLINICAL; GRANULOCYTES; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LEUKOCYTES, MONONUCLEAR; PLASMA; RISK ASSESSMENT; TIME FACTORS; TISSUE SCAFFOLDS; TOXICITY TESTS;

EID: 84856866938     PISSN: 1547691X     EISSN: None     Source Type: Journal    
DOI: 10.3109/1547691X.2011.613419     Document Type: Article

References (28)

1. Baselga, J., Carbonell, X., Castada-Soto, N. J., Clemens, M., Green, M., Harvey, V., Morales, S., Barton, C. and Ghahramani, P. 2005. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol. 23:2162-2171. (Pubitemid 46218708)
2. Bugelski, P. J., Achuthanandam, R., Capocasale, R. J., Treacy, G. and Bouman-Thio, E. 2009. Monoclonal antibody-induced cytokinerelease syndrome. Expert Rev Clin Immunol. 5:499-521.
3. Chang, T. W., Testa, D., Kung, P. C., Perry, L., Dreskin, H. J. and Goldstein, G. 1982. Cellular origin and interactions involved in interferon production induced by OKt3 monoclonal antibody. J Immunol. 128:585-589. (Pubitemid 12168405)
4. Dillman, R. O. 1999. Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev. 18:465-471. (Pubitemid 30365324)
5. Eastwood, D., Findlay, L., Poole, S., Bird, C., Wadhwa, M., Moore, M., Burns, C., Thorpe, R. and Stebbings, R. 2010. Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells. Br J Pharmacol. 161:512-526.
6. Findlay, L., Eastwood, D., Stebbings, R., Sharp, G., Mistry, Y., Ball, C., Hood, J., Thorpe, R. and Poole, S. 2010. Improved in vitro methods to predict the in vivo toxicity in man of therapeutic monoclonal antibodies including TGN1412. J Immunol Methods. 352:1-12.
7. Findlay, L., Sharp, G., Fox, B., Ball, C., Robinson, C. J., Bird, C., Stebbings, R., Eastwood, D., Wadhwa, M., Poole, S., Thorpe, R. and Thorpe, S. J. 2011. Endothelial cells co-stimulate peripheral blood mononuclear cell responses to monoclonal antibody TGN1412 in culture. Cytokine. 55:141-151.
8. Gaston, R. S., Deierhoi, M. H., Patterson, T., Prasthofer, E., Julian, B. A., Barber, W. H., Laskow, D. A., Diethelm, A. G. and Curtis, J. J. 1991. OKT3 first-dose reaction: Association with T-cell subsets and cytokine release. Kidney Int. 39:141-148.
9. Goldstein, G., Norman, D. J., Henell, K. R. and Smith, I. L. 1988. Pharmacokinetic study of orthoclone OKT3 serum levels during treatment of acute renal allograft rejection. Transplantation. 46:587-589.
10. Gribble, E. J., Sivakumar, P. V., Ponce, R. A. and Hughes, S. D. 2007. Toxicity as a result of immunostimulation by biologics. Expert Opin Drug Metab Toxicol. 3:209-234. (Pubitemid 47321517)
11. Hansel, T. T., Kropshofer, H., Singer, T., Mitchell, J. A. and George, A. J. 2010. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov. 9:325-338.
12. Hustmyer, F. G., Girasole, G. and Manolagas, S. C. 1992. Signal-dependent pleiotropic regulation of lymphocyte proliferation and cytokine production by 1,25-dihydroxyvitamin D3: Potent modulation of the hormonal effects by phorbol esters. Immunology. 77:520-526. (Pubitemid 23000471)
13. Ikuta, S., Kirby, J. A., Shenton, B. K., Givan, A. L. and Lennard, T. W. 1991. Human endothelial cells: effect of TNF on peripheral blood mononuclear cell adhesion. Immunology. 73:71-76.
14. Klastersky, J. 2006. Adverse effects of the humanized antibodies used as cancer therapeutics. Curr Opin Oncol. 18:316-320. (Pubitemid 44297239)
15. Lan, W., Harmon, D. C., Wang, J. H., Shorten, G. D. and Redmond, P. H. 2005. Activated endothelial interleukin-1,-6, and -8 concentrations and intercellular adhesion molecule-1 expression are attenuated by lidocaine. Anesth Analg. 100:409-412. (Pubitemid 40170534)
16. Langeggen, H., Namork, E., Johnson, E. and Hetland, G. 2003. HUVEC take up opsonized zymosan particles and secrete cytokines IL-6 and IL-8 in vitro. FEMS Immunol Med Microbiol. 36:55-61. (Pubitemid 36515084)
17. Lenz, H. J. 2007. Management and preparedness for infusion and hypersensitivity reactions. Oncologist. 12:601-609.
18. Locksley, R. M., Heinzel, F. P., Shepard, H. M., Agosti, J., Eessalu, T. E., Aggarwal, B. B. and Harlan, J. M. 1987. Tumor necrosis factors alpha and beta differ in their capacities to generate IL-1 release from human endothelial cells. J Immunol. 139:1891-1895. (Pubitemid 17141620)
19. Mackay, F., Loetscher, H., Stueber, D., Gehr, G. and Lesslauer, W. 1993. Tumor necrosis factor (TNF)-induced cell adhesion to human endothelial cells is under dominant control of one TNF receptor type, TNF-R55. J Exp Med. 177:1277-1286. (Pubitemid 23117119)
20. Moreau, T., Coles, A., Wing, M., Isaacs, J., Hale, G., Waldmann, H. and Compston, A. 1996. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain. 119 (Pt 1):225-237. (Pubitemid 26077567)
21. Randolph, G. J., Sanchez-Schmitz, G., Liebman, R. M. and Schel, K. 2002. CD16+ (FcRIII+) subset of human monocytes preferentially becomes migratory dendritic cells in a model tissue setting. J Exp Med. 196:517-527.
22. Sandilands, G. P., Wilson, M., Huser, C., Jolly, L., Sands, W. A. and McSharry, C. 2010. Were monocytes responsible for initiating the cytokine storm in the TGN1412 clinical trial tragedy Clin Exp Immunol. 162:516-527.
23. St Clair, E. W., Wagner, C. L., Fasanmade, A. A., Wang, B., Schaible, T., Kavanaugh, A. and Keystone, E. C. 2002. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: Results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46:1451-1459. (Pubitemid 34620190)
24. Stebbings, R., Findlay, L., Edwards, C., Eastwood, D., Bird, C., North, D., Mistry, Y., Dilger, P., Liefooghe, E., Cludts, I., Fox, B., Tarrant, G., Robinson, J., Meager, T., Dolman, C., Thorpe, S. J., Bristow, A., Wadhwa, M., Thorpe, R. and Poole, S. 2007. "Cytokine storm" in the Phase I trial of monoclonal antibody TGN1412: Better understanding the causes to improve preclinical testing of immunotherapeutics. J Immunol. 179:3325-3331.
25. Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D. and Panoskaltsis, N. 2006. Cytokine storm in a Phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 355:1018-1028. (Pubitemid 44343545)
26. Wing, M. 2008. Monoclonal antibody first dose cytokine release syndromes-mechanisms and prediction. J Immunotoxicol. 5:11-15. (Pubitemid 351431265)
27. Wing, M. G., Moreau, T., Greenwood, J., Smith, R. M., Hale, G., Isaacs, J., Waldmann, H., Lachmann, P. J. and Compston, A. 1996. Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: Involvement of CD16 (FcRIII) and CD11a/CD18 (LFA-1) on NK cells. J Clin Invest. 98:2819-2826. (Pubitemid 26427411)
28. Wing, M. G., Waldmann, H., Isaacs, J., Compston, D. A. and Hale, G. 1995. Ex-vivo whole blood cultures for predicting cytokine-release syndrome: Dependence on target antigen and antibody isotype. Ther Immunol. 2:183-190. (Pubitemid 27433380)